Positive topline results from ph2b in head & neck cancer
Filed with ASX · · 4 pages · English
In the deck
Earlier from Immutep
- Immutep completes underwritten retail entitlement offer
- Immutep completes institutional pro-rata offer & placement
- Immutep announces Ph 3 clinical trial collaboration with MSD
- Immutep Capital Raising Presentation
- A$100 million fully underwritten equity raising
Later from Immutep
- Webcast slides for new Efti clinical data in 1st line HNSCC
- Positive results in TACTI-003 for 1L HNSCC cohort B patients
- Webcast to discuss data presented at ESMO Plenary Session
- Regulatory Clearance received for Phase 1 trial of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep